Average number of infections per drug-susceptible (DS) TB case per year |
β
|
10.7 [5.8–13.6] |
Estimated |
Average number of infections per MDR-TB case per year |
β
mdr
|
2.00 [1.62–2.62] |
Estimated |
Per care seeking attempt, probability of seeking care in the public sector (following RNTCP scale-up) |
p
max
|
0.34 [0.25–0.58] |
Estimated to get reported notifications from 1997–2015 |
Proportion of MDR-TB cases whose drug resistance is recognized at the point of TB diagnosis and who start appropriate treatment |
q
max
|
0.07 [0.06–0.09] |
Estimated to get reported notifications from 2007–2015 |
Reduction in force of infection owing to previous infection |
C
|
0.5 |
Assumed |
Proportion of infections undergoing ‘rapid’ progression |
k
|
0.15 |
Vynnycky and Fine, 1997 [42] |
Rate of breakdown from remote infection to active disease |
h
|
0.001 y-1
|
Horsburgh et al., 2010 [43] |
Rate corresponding to the delay from the start of symptoms to the initiation of treatment (whether in public or private sector) |
r
|
3.29 y-1 [0.83–5.70] |
Estimated |
Mean duration of first-line treatment |
|
2 y-1
|
Corresponding to 6 months of treatment duration |
Rate of default from non-RNTCP treatment |
d
RNTCP
|
1.06 y-1
|
Uplekar et al. 1998 [29] |
Rate of default from RNTCP treatment |
d
non-RNTCP
|
0.049 y-1
|
Corresponds to 4.8% default in RNTCP (TB India, 2015 [34]) (averaged over smear-positive, smear-negative and extrapulmonary TB) |
Rate of repeat care seeking after recurrence or failure |
w
|
4 y-1
|
Corresponds to 3 months of delay period |
Annual recurrence rate |
|
0.003 y-1
|
Corresponds to lifetime recurrence risk of 17% (Sun et al., 2013 [44]) |
Rate of primary MDR acquisition from patient treated under RNTCP |
m
|
0.02 y-1
|
TB India, 2015 [34] |
Mean duration of second-line treatment |
|
0.5 y-1
|
Corresponding to 2 years of treatment duration |
Spontaneous cure rate |
|
0.166 y-1
|
Corresponds to 50% spontaneous cure in 3 years alongside with TB mortality (Tiemersma et al., 2011 [26]) |
Proportion cure of drug-susceptible (DS)-TB in RNTCP after first-line treatment |
α
pub
|
0.87 |
TB India, 2015 [34] |
Proportion cure of DS-TB in non-RNTCP after first-line treatment |
α
prv
|
0.51 |
Uplekar et al., 1998 [29] |
Proportion cure of MDR-TB in RNTCP after first-line treatment (excluding self-cure) |
α’
pub
|
0.24 |
TB India, 2015 [34] |
Proportion cure of MDR-TB in non-RNTCP after first-line treatment |
α’
prv
|
0 |
Assumed |
Proportion cure of MDR-TB with second-line treatment (excluding self-cure) |
α’
pub2
|
0.48 |
TB India, 2014 [45] |
Per-capita mortality hazard before diagnosis |
μ
UTB
|
0.086 (95% CI 0.075–0.11) y-1
|
See Additional file 1
|
Mortality hazard during RNTCP treatment |
μ
RNTCP
|
0.076 (95% CI 0.069–0.095) y-1
|
See Additional file 1
|
Mortality hazard during non-RNTCP treatment |
μ
non-RNTCP
|
0.27 (95% CI 0.22–0.33) y-1
|
See Additional file 1
|
Mortality hazard following default and treatment failure |
μ
B
|
0.28 (95% CI 0.22–0.36) y-1
|
See Additional file 1
|